EUpolicy

Market Access

Beyond the Bill: how do we make medicines affordable without...

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

News

GLP-1s from Novo, Lilly 'should be first-line in obesity'

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.

News

Sanofi faces EU antitrust probe into vaccine business

Sanofi has confirmed it is being investigated by the European Commission for potentially anticompetitive activity in its vaccines business.

R&D

How Europe can harness the full potential of biosimilars

Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.

R&D

No longer the little fish: How Europe is holding its own thr...

It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.

Market Access

neurotech representation of head in code

Neurotech patents in Europe: Methods, medical devices, and t...

The field of neurotechnology is rapidly evolving, bringing together advances in neuroscience, engineering, materials science, and computing.